AR017973A1 - Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo - Google Patents

Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo

Info

Publication number
AR017973A1
AR017973A1 ARP990100239A ARP990100239A AR017973A1 AR 017973 A1 AR017973 A1 AR 017973A1 AR P990100239 A ARP990100239 A AR P990100239A AR P990100239 A ARP990100239 A AR P990100239A AR 017973 A1 AR017973 A1 AR 017973A1
Authority
AR
Argentina
Prior art keywords
formulation
antibody
storage
formulations
present
Prior art date
Application number
ARP990100239A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9800170A external-priority patent/SE9800170D0/xx
Priority claimed from SE9800766A external-priority patent/SE9800766D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR017973A1 publication Critical patent/AR017973A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP990100239A 1998-01-22 1999-01-21 Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo AR017973A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9800170A SE9800170D0 (sv) 1998-01-22 1998-01-22 Formulation
SE9800766A SE9800766D0 (sv) 1998-03-09 1998-03-09 Formulation

Publications (1)

Publication Number Publication Date
AR017973A1 true AR017973A1 (es) 2001-10-24

Family

ID=26663196

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100239A AR017973A1 (es) 1998-01-22 1999-01-21 Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo

Country Status (3)

Country Link
AR (1) AR017973A1 (fr)
AU (1) AU2444899A (fr)
WO (1) WO1999037329A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270150B2 (fr) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
EP1254666A4 (fr) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd Compositions d'anticorps stables et preparations pour injection
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
EP1698640B2 (fr) * 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Methode de stabilisation d'anticorps et preparation d'anticorps de type solution stabilisee
WO2005035573A1 (fr) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Methode de stabilisation de solution proteinique
ATE518888T1 (de) 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
EP1712240B1 (fr) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Preparation medicamenteuse aqueuse stable contenant un anticorps
NZ549893A (en) * 2004-03-24 2010-05-28 Facet Biotech Corp Use of anti-alpha5beta1 antibodiesin a stabilising solution to inhibit cancer cell proliferation
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
CA2649907A1 (fr) * 2006-04-21 2007-11-01 Novartis Ag Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2013103783A1 (fr) * 2012-01-04 2013-07-11 Sanofi Us Anticorps murins il-13
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
HUE049282T2 (hu) 2012-09-07 2020-09-28 Coherus Biosciences Inc Adalimumab stabil vizes formulációi
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
EP0465513A1 (fr) * 1989-03-27 1992-01-15 Centocor, Inc. COMPOSITIONS SERVANT A STABILISER DES ANTICORPS D'IMMUNOGLOBULINE IgM
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
ES2202310T3 (es) * 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions

Also Published As

Publication number Publication date
WO1999037329A1 (fr) 1999-07-29
AU2444899A (en) 1999-08-09

Similar Documents

Publication Publication Date Title
AR017973A1 (es) Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo
KR950014915B1 (ko) 탈시알로당단백-포함화합물
CA1329543C (fr) Formulation a base d'hormone de croissance humaine
KR101363237B1 (ko) 증강된 비율의 감마 인터페론 및 알파 인터페론을 포함하는안정화된 제형
Gresser et al. Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice.
DE69434418D1 (de) Orale Dareichungsform
JPH03504967A (ja) 血液脳関門を介しての神経ペプチド運搬のためのキメラ性ペプチド
JPH03502197A (ja) 新規な抗炎症剤
BRPI0616300A2 (pt) formulaÇço aquosa de hfsh
AR052198A1 (es) Formulaciones anticuerpo anti a beta
PT88626B (pt) Processo para a preparacao de um factor de crescimento polipeptidico proveniente de leite
Tsutsumi et al. PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency
CA2376894C (fr) Composition pharmaceutique comprenant une proteine et une ectoine
KR900015749A (ko) 인터루킨-1제형
ES2908141T3 (es) Formulaciones y dosis de cannabinoides
DK1173476T3 (da) Funktionelle sojabönneproteiner
JPH06247872A (ja) 高濃度ｔｃｆ製剤
JPH0640938A (ja) Ｈｇｆ含有製剤
ES2329204T3 (es) Composicion antiviral que comprende interferon en forma de gotas nasales.
CN100553674C (zh) 一种重组人甲状旁腺激素(1-84)药物组合物及其制备方法
JPH0441421A (ja) 肺吸収組成物
JPS6360940A (ja) 白内障の予防または治療剤
JPH0543478A (ja) ＩＬ−１α安定化医薬製剤
ES2226326T3 (es) Hormona de crecimiento humana para estimular la hematopoyesis y la reconstitucion del sistema inmune despues del trasplante de celulas madre hematopoyeticas en seres humanos.
JP2655667B2 (ja) 抗体を含有する安定水性組成物